The North American antinuclear antibody test market size is predicted to be worth USD 879.4 million by 2028 from USD 496.8 million in 2023, growing at a CAGR of 12.1% from 2023 to 2028.
The growing prevalence of autoimmune diseases majorly drives the antinuclear antibody test market in North America. Factors such as lifestyle changes, consumption of alcohol, obesity, exposure to toxins, side effects of medication and genetic effects have been identified as the primary causes of autoimmune disorders. The antinuclear antibody test, a blood test that detects antinuclear antibodies in the blood, is essential in identifying these harmful antibodies that attack healthy cells. Approximately 50 million Americans are currently suffering from one or more autoimmune diseases, with women being more affected than men. The population exhibits almost 100 different types of autoimmune diseases, leading to rising demand for antinuclear antibody tests and thus contributing to regional market growth. Companies operating in the North American antinuclear antibody test market can capitalize on this growth by developing innovative solutions and expanding their reach to serve the increasing demand for antinuclear antibody testing.
The advancements in testing processes further contribute to the growth of the North American antinuclear antibody test market. Researchers are constantly adding advanced features to testing kits to improve their accuracy while increasing product launches and government support drive the market growth in North America. The increased investments of North American countries to develop affordable antinuclear antibody test kits are a significant boost to the regional market. The key market players also invest heavily in the development of new testing solutions and technological advancements, which favors regional market growth. The emergence of startups in the market is contributing to the increasing demand for antinuclear antibody testing and this is further supported by the growing awareness of the importance of the antinuclear antibody test in maintaining a healthy body to support the market growth in the North American region.
The rising incidence of chronic diseases, such as cancer and diabetes in North America, the growing involvement of technological advancements in the development of testing kits, increasing healthcare expenditure in North America, the growing investments by the governmental and non-governmental organizations for the development of affordable and efficient testing solutions and favorable regulatory environment in North America for the development and approval of new testing solutions boost the growth rate of the North American market.
The lack of skilled professionals for the proper inlays of the blood for antinuclear antibody testing primarily hampers the regional market growth. Inaccurate results in the antinuclear antibody test can also pose a challenge and restrict market growth. This could lead to incorrect diagnoses, potentially impacting patient outcomes and reducing trust in the testing process. The availability of alternative tests and the lack of proper infrastructure facilities could also impede the market growth. Alternative tests and facilities that offer similar testing solutions could limit demand for antinuclear antibody tests, thereby impacting the market's growth prospects.
This research report on the North American antinuclear antibody test market has been segmented and sub-segmented into the following categories.
By End User:
North America had the largest share of the global antinuclear antibody test market in 2022 and is estimated to register the same domination throughout the forecast period. The growing adoption of advanced medical products and diagnostics tests for disease or infection detection and the measures taken by the North American governments to approve products that provide accurate results for the antinuclear antibody test support the regional market growth. The growing number of Covid-19 cases in the region has also contributed to the demand for antinuclear antibody tests and drive the regional market growth. People suffering from coronavirus disease often exhibit positive antinuclear antibody results, and a weakened immune system is commonly observed in Covid-19 positive patients. As a result, the demand for antinuclear antibody tests has surged, contributing to the overall growth of the market. To further promote awareness of the presence of antinuclear antibodies in the body and their impact on a person's health, the government and manufacturing centers have conducted several awareness programs. These initiatives have helped increase understanding among individuals and healthcare professionals about the importance of accurate and reliable antinuclear antibody testing, ultimately driving the growth of the market.
The U.S. had a dominating share of the North American market in 2022 and is predicted to hold the largest share of the North American market during the forecast period owing to the growing number of manufacturing facilities and clinical trial centers in the U.S. Around 3-15% of healthy individuals have antinuclear antibodies, with the prevalence being higher among individuals aged over 65. As people age, their nutritional intake tends to decrease, leading to a reduction in antibody production.
Canada is another noteworthy regional market in North America and is expected to hold a notable share of the North American market during the forecast period. The growing presence of laboratories in the country majorly drives the Canadian market growth. Health Canada has also implemented several measures to ensure accurate reporting of antinuclear antibody tests, which has further contributed to the growth of the market in the region.
KEY MARKET PLAYERS
Companies playing a dominant role in the North American antinuclear antibody test market profiled in this report are Zeus Scientific Inc., Inova Diagnostics, Immuno Concepts, Euroimmun AG, Antibodies Inc., Thermo Fisher Scientific inc., Trinity Biotech plc, ERBA Diagnostics Inc., Bio-Rad Laboratories Inc., and Alere Inc.
The North American antinuclear antibody test market is estimated to grow at a CAGR of 12.1% from 2023 to 2028.
The growing prevalence of autoimmune diseases, advances in testing processes, increasing government support, and increasing investment by key players majorly drive the North American antinuclear antibody test market.
Some of the challenges facing the North America Antinuclear Antibody Test Market include a lack of skilled professionals to perform the test, inaccurate results, availability of alternative tests, and lack of proper infrastructure facilities.
The United States and Canada are both contributing to the growth of the Antinuclear Antibody Test Market in North America, with the United States having a larger share due to the presence of manufacturing facilities and clinical trial centers.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]